Xtl Biopharmaceuticals (XTLB) Other Non Operating Income (2013 - 2024)
Xtl Biopharmaceuticals (XTLB) posted quarterly Other Non Operating Income of $2000.0 for Q4 2024, down 81.82% year-on-year from $11000.0 in Q1 2024, and down 84.62% on a QoQ basis from $13000.0 in Q3 2024.
Xtl Biopharmaceuticals (XTLB) Other Non Operating Income (2013 - 2024) Analysis & Trends
Xtl Biopharmaceuticals (XTLB) has reported Other Non Operating Income for 9 consecutive years, with $2000.0 the latest figure, recorded in Q4 2024.
- Quarterly Other Non Operating Income fell 81.82% year-over-year to $2000.0 in Q4 2024, while the trailing twelve-month figure through Dec 2024 was $34000.0 (down 17.07% YoY) and the FY2025 annual result came in at $60000.0, up 76.47% from the prior year.
- Other Non Operating Income eased to $2000.0 in Q4 2024 per XTLB's latest filing, from $13000.0 in the prior quarter.
- Over the last five years, Other Non Operating Income for XTLB reached as high as $495000.0 in Q2 2022 and fell as low as -$776000.0 in Q2 2021.
- A 5-year average of -$9437.5 and a median of $9500.0 in 2023 frame the typical range for Other Non Operating Income.
- Annual changes were most pronounced in 2021 — Other Non Operating Income sank 6069.23% — and 2023, when it surged 300.0%.
- Year by year, Other Non Operating Income stood at $29000.0 in 2020, then sank by 2775.86% to -$776000.0 in 2021, then soared by 101.55% to $12000.0 in 2022, then slipped by 8.33% to $11000.0 in 2023, then tumbled by 81.82% to $2000.0 in 2024.
- According to Business Quant data, Other Non Operating Income over the past three periods registered $2000.0, $13000.0, and $9000.0 for Q4 2024, Q3 2024, and Q2 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Xtl Biopharmaceuticals | 2.60 Bn | 2.60 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 2,000.00 |
| Sep 30, 2024 | 13,000.00 |
| Jun 30, 2024 | 9,000.00 |
| Mar 31, 2024 | 10,000.00 |
| Dec 31, 2023 | 11,000.00 |
| Sep 30, 2023 | 9,000.00 |
| Jun 30, 2023 | 9,000.00 |
| Mar 31, 2023 | 12,000.00 |
| Sep 30, 2022 | 12,000.00 |
| Jun 30, 2022 | 495,000.00 |
| Mar 31, 2022 | 3,000.00 |
| Jun 30, 2021 | -776,000.00 |
| Dec 31, 2020 | 29,000.00 |
| Sep 30, 2020 | -9,000.00 |
| Jun 30, 2020 | 13,000.00 |
| Mar 31, 2020 | 7,000.00 |
| Sep 30, 2019 | 20,000.00 |
| Jun 30, 2019 | 17,000.00 |
| Mar 31, 2019 | 21,000.00 |
| Sep 30, 2018 | 131,000.00 |